On Mar. 18, 2020, Emergent BioSolutions announced an agreement with Vaxart, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxartﾒs experimental oral vaccine candidate for coronavirus disease (COVID-19).